Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | HTR1B | P28222 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | ESR1 | P03372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28463114 | 0.83 | ALDH1A1 (0.41) | KDM4EL3MBTL1MEN1CYP1A2CYP3A4 | |
| SCHEMBL21268198 | 0.83 | CYP1A2 (0.39) | L3MBTL1MEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL7389250 | 0.76 | KDM4E (0.42) | KDM4EHTR1BL3MBTL1TP53MAPK1 | |
| SCHEMBL183184 | 0.76 | KDM4E (0.47) | KDM4EHTR1BL3MBTL1TP53MAPK1 | |
| SCHEMBL28571285 | 0.75 | CYP2D6 (0.37) | KDM4EMAPK1MEN1CYP1A2CYP3A4 | |
| SCHEMBL1290474 | 0.75 | KDM4E (0.61) | KDM4EHTR1BL3MBTL1TP53MAPK1 | |
| SCHEMBL1299208 | 0.74 | POLB (0.35) | L3MBTL1MAPK1MEN1CYP1A2CYP3A4 | |
| SCHEMBL27690633 | 0.74 | CYP1A2 (0.40) | HTR1BMEN1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL28166627 | 0.74 | MAPT (0.45) | KDM4EL3MBTL1MAPK1CYP1A2CYP2C9 | |
| SCHEMBL16240200 | 0.74 | KDM4E (0.44) | KDM4EHTR1BTP53MAPK1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2499282-B1 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR | NEUROGENETIC PHARMACEUTICALS INC (US) | 2015-04-22 | — | — | EP | disclosed |
| US-8871460-B2 | Gamma-secretase modulatory compounds, methods for identifying same, and uses therefor | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20120289558-A1 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR | NEUROGENETIC PHARMACEUTICALS, INC. | 2012-11-15 | — | — | US | disclosed |
| EP-2499282-A2 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR | NeuroGenetic Pharmaceuticals, Inc. (US) | 2012-09-19 | — | — | EP | disclosed |
| WO-2011057214-A2 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR | NEUROGENETIC PHARMACEUTICALS, INC. (US) | 2011-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120289558-A1 | GAMMA-SECRETASE MODULATORY COMPOUNDS, METHODS FOR IDENTIFYING SAME, AND USES THEREFOR | BACE1, GSAP, BACE2 | KDM4E 3502/4885HTR1B 4009/4885L3MBTL1 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.